News
CRVS
1.790
+1.70%
0.030
Corvus Pharmaceuticals Is Maintained at Neutral by Mizuho
Dow Jones · 20h ago
Corvus Pharmaceuticals Price Target Maintained With a $3.50/Share by Mizuho
Dow Jones · 20h ago
Mizuho Maintains Neutral on Corvus Pharma, Maintains $3.5 Price Target
Benzinga · 20h ago
Weekly Report: what happened at CRVS last week (0318-0322)?
Weekly Report · 3d ago
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 5d ago
Corvus Pharmaceuticals: Insider Ownership Raises Power Concentration Concerns
TipRanks · 03/21 06:01
Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Dow Jones · 03/20 11:24
Corvus Pharmaceuticals Price Target Cut to $7.00/Share From $8.00 by Oppenheimer
Dow Jones · 03/20 11:24
Oppenheimer Maintains Outperform on Corvus Pharma, Lowers Price Target to $7
Benzinga · 03/20 11:14
CRVS Stock Earnings: Corvus Pharma Misses EPS for Q4 2023
Corvus Pharma reported earnings per share of -14 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -12 cents. Corvus pharma reported results for the last quarter of 2013.
Investorplace · 03/20 00:53
Corvus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Corvus Pharmaceuticals Inc reports results for the quarter ended in December. Reported revenue was zero; analysts expected zero. The company reported a quarterly loss of $6.65 million. Corvus pharmaceuticals Inc shares had risen by 8.0% this quarter.
Reuters · 03/19 21:01
Corvus Pharma Q4 EPS $(0.14) Misses $(0.12) Estimate
Benzinga · 03/19 20:04
Corvus Pharmaceuticals GAAP EPS of -$0.14 misses by $0.01
Corvus Pharmaceuticals GAAP EPS of -$0.14 misses by $0.01. As of December 31, 2023, Corvus had cash, cash equivalents and marketable securities of $27.1 million. The company's Q4 GAAP revenue was $8.2 million, down from $9.3 million in Q3.
Seeking Alpha · 03/19 20:04
*Corvus Pharma: Soquelitinib Advancing Towards Initial Enrollment for Registrational Phase 3 Clinical Trial for PTCL and Randomized Phase 1 Clinical Trial for Atopic Dermatitis >CRVS
Dow Jones · 03/19 20:04
Press Release: Corvus Pharmaceuticals Provides -2-
Research and development expenses for the three months and full year ended December 31, 2023 totaled $4.0 million and $16.5 million, respectively. The Company's lead product candidate is soquelitinib, an investigational drug that selectively inhibits ITK. Corvus will host a conference call and webcast on March 19, 2024 to discuss its financial results.
Dow Jones · 03/19 20:02
*Corvus Pharmaceuticals 4Q Loss $6.65M >CRVS
Dow Jones · 03/19 20:02
Press Release: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for relapsed PTCL. Orphan drug designation and new interim data from Phase 1/1b clinical trial.
Dow Jones · 03/19 20:02
Corvus: Q4 Earnings Snapshot
Corvus Pharmaceuticals Inc. Reported a loss of $6.7 million in its fourth quarter. On a per-share basis, the company said it had a Loss of 14 cents. Corvus reported a profit of $2.2 million in the third quarter.
Barchart · 03/19 15:08
Options Volatility and Implied Earnings Moves Today, March 19, 2024
TipRanks · 03/19 12:06
More
Webull provides a variety of real-time CRVS stock news. You can receive the latest news about Corvus Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.